Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for ‘sick fat’ and metabolic disease

References

• Kushner RF, Roth JL. Assessment of the obese patient. Endocrinol. Metab. Clin. North Am.32(4), 915–933 (2003).
   PubMed Web of Science ®Google Scholar
• Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiol.1(1), 39–59 (2005).
   PubMedGoogle Scholar
• Bays HE, Gonzalez-Campoy JM et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev. Cardiovasc. Ther.6(3), 343–368 (2008).
   PubMedGoogle Scholar
• Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of Type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab.89(2), 463–478 (2004).
   PubMed Web of Science ®Google Scholar
• Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol.1(4), 389–420 (2006).
   Web of Science ®Google Scholar
• Bays HE, Gonzalez-Campoy JM, Henry RR et al. Is adiposopathy (sick fat) an endocrine disease? Int. J. Clin. Pract.62(10), 1474–1483 (2008).
   PubMed Web of Science ®Google Scholar
• Khan T, Muise ES, Iyengar P et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol. Cell. Biol.29(6), 1575–1591 (2009).
   PubMed Web of Science ®Google Scholar
• Bays HE, Laferrere B, Dixon J et al. Adiposopathy and bariatric surgery: is ‘sick fat’ a surgical disease? A consensus from the adiposopathy and bariatric surgery group. Int. J. Clin. Pract.(2009) (In Press).
   Google Scholar
• Bluher M. Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes117(6), 241–250 (2009).
   PubMed Web of Science ®Google Scholar
• Bays H. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev. Cardiovasc. Ther.3(3), 393–404 (2005).
   PubMedGoogle Scholar
• Bays HE. ‘Sick fat,’ metabolic disease, and atherosclerosis. Am. J. Med.122(1 Suppl.), S26–S37 (2009).
   PubMed Web of Science ®Google Scholar
• Bays H, Blonde L, Rosenson R. Adiposopathy: how do diet, exercise, weight loss and drug therapies improve metabolic disease? Expert Rev. Cardiovasc. Ther.4(6), 871–895 (2006).
   PubMedGoogle Scholar
• Bays HE, Rodbard RW, Schorr AB, González-Campoy JM. Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk. Curr. Treat Options Cardiovasc. Med.9(4), 259–271 (2007).
   PubMedGoogle Scholar
• Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int. J. Clin. Pract.61(5), 737–747 (2007).
   PubMed Web of Science ®Google Scholar
• Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J. Am. Coll. Cardiol.53(21), 1925–1932 (2009).
   PubMed Web of Science ®Google Scholar
• Davenport DL, Xenos ES, Hosokawa P, Radford J, Henderson WG, Endean ED. The influence of body mass index obesity status on vascular surgery 30-day morbidity and mortality. J. Vasc. Surg.49(1), 140–147, 147 (2009).
   PubMedGoogle Scholar
• Orpana HM, Berthelot JM, Kaplan MS, Feeny DH, McFarland B, Ross NA. BMI and mortality: results from a national longitudinal study of canadian adults. Obesity (Silver.Spring)DOI: 10.1038/oby.2009.191 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J. Clin. Endocrinol. Metab.89(6), 2569–2575 (2004).
   PubMed Web of Science ®Google Scholar
• Tsai AG, Wadden TA. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann. Intern. Med.142(1), 56–66 (2005).
   PubMed Web of Science ®Google Scholar
• Rubino F. Is Type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care31(Suppl. 2), S290–S296 (2008).
   PubMedGoogle Scholar
• Patel MR, Donahue M, Wilson PW, Califf RM. Clinical trial issues in weight-loss therapy. Am. Heart J.151(3), 633–642 (2006).
   PubMedGoogle Scholar
• Bays H. Adiposopathy: the endocannabinoid system as a therapeutic treatment target for dysfunctional ‘sick’ fat. CJHP19(1), 32–39 (2007).
   Google Scholar
• Hausenloy DJ. Contrave TM: novel treatment for obesity. Clin. Lipidol.4(3), 279–285 (2009).
   Web of Science ®Google Scholar
• Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J. Clin. Psychiatry68(8), 1226–1229 (2007).
   PubMed Web of Science ®Google Scholar
• Gadde KM, Yonish GM, Foust MS, Tam PY, Najarian T. A 24-week randomized controlled trial of VI-0521, a combination weight loss therapy, in obese adults. Presented at: Program and abstracts of the Annual Scientific Scientific Meeting of NAASO, The Obesity Society, 2006. Boston, MA, USA, 20–24 October 2006.
   Google Scholar
• Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann. Intern. Med.143(5), 380–385 (2005)
   PubMed Web of Science ®Google Scholar
• Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin. Drug Saf.4(6), 1083–1095 (2005).
   PubMedGoogle Scholar
• Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med.142(7), 525–531 (2005).
   PubMed Web of Science ®Google Scholar
• Varady KA, Tussing L, Bhutani S, Braunschweig CL. Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women. Metabolism58(8), 1096–1101 (2009).
   PubMed Web of Science ®Google Scholar
• Ratner RE. An update on the Diabetes Prevention Program. Endocr. Pract.12(Suppl. 1), 20–24 (2006).
   PubMedGoogle Scholar
• Nair RP, Ren J. Pharmacotherapy of obesity–benefit, bias and hyperbole. Curr. Med. Chem.16(15), 1888–1897 (2009).
   PubMedGoogle Scholar
• Bays H, Dujovne C. Anti-obesity drug development. Expert Opin. Investig. Drugs11(9), 1189–1204 (2002).
   PubMed Web of Science ®Google Scholar
• Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes. Res.12(8), 1197–1211 (2004).
   PubMedGoogle Scholar
• Magni P, Dozio E, Ruscica M et al. Feeding behavior in mammals including humans. Ann. NY Acad. Sci.1163, 221–232 (2009).
   PubMed Web of Science ®Google Scholar
• Lenard NR, Berthoud HR. Central and peripheral regulation of food intake and physical activity: pathways and genes. Obesity (Silver.Spring)16(Suppl. 3) S11–S22 (2008).
   PubMed Web of Science ®Google Scholar
• Garfield AS, Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. J. Physiol.587(Pt 1), 49–60 (2009).
   PubMed Web of Science ®Google Scholar
• Akana SF. Feeding and stress interact through the serotonin 2C receptor in developing mice. Physiol. Behav.94(4), 569–579 (2008).
   PubMedGoogle Scholar
• Scalfi L, D’Arrigo E, Carandente V, Coltorti A, Contaldo F. The acute effect of dexfenfluramine on resting metabolic rate and postprandial thermogenesis in obese subjects: a double-blind placebo-controlled study. Int. J. Obes. Relat. Metab. Disord.17(2), 91–96 (1993).
   PubMedGoogle Scholar
• Van Gaal LF, Vansant GA, Steijaert MC, De Leeuw I. Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction. Metabolism44(2 Suppl. 2), 42–45 (1995).
   PubMedGoogle Scholar
• Lafreniere F, Lambert J, Rasio E, Serri O. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study. Int. J. Obes. Relat. Metab. Disord.17(1), 25–30 (1993).
   PubMedGoogle Scholar
• Kogon MM, Krauchi K, van der Velde V, Van der Werf H, Keller U. Psychological and metabolic effects of dietary carbohydrates and dexfenfluramine during a low-energy diet in obese women. Am. J. Clin. Nutr.60(4), 488–493 (1994).
   PubMedGoogle Scholar
• Doucet E, St Pierre S, Almeras N, Mauriege P, Richard D, Tremblay A. Changes in energy expenditure and substrate oxidation resulting from weight loss in obese men and women: is there an important contribution of leptin? J. Clin. Endocrinol. Metab.85(4), 1550–1556 (2000).
   PubMed Web of Science ®Google Scholar
• Levitsky DA, Troiano R. Metabolic consequences of fenfluramine for the control of body weight. Am. J. Clin. Nutr.55(1 Suppl), S167– S172 (1992).
   Google Scholar
• Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs67(1), 27–55 (2007).
   PubMed Web of Science ®Google Scholar
• Recasens MA, Barenys M, Sola R, Blanch S, Masana L, Salas-Salvado J. Effect of dexfenfluramine on energy expenditure in obese patients on a very-low-calorie-diet. Int. J. Obes. Relat. Metab. Disord.19(3), 162–168 (1995).
   PubMedGoogle Scholar
• Wacker DA, Miller KJ. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases. Curr. Opin. Drug Discov. Devel.11(4), 438–445 (2008).
   PubMedGoogle Scholar
• Miller KJ. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. Mol. Interv.5(5), 282–291 (2005).
   PubMed Web of Science ®Google Scholar
• Thomsen WJ, Grottick AJ, Menzaghi F et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther.325(2), 577–587 (2008).
   PubMed Web of Science ®Google Scholar
• Smith SR, Prosser W, Donahue D, Anderson C, Shanahan W. APD356–004 study group. Lorcaserin (APD356), a selective 5-HT2C agonist, safely induces weight loss in a 12-week study of healthy obese patients. Presented at: American Diabetes Association 66th Annual Scientific Sessions. Washington DC USA, 6 December 2006.
   Google Scholar
• Sugden K, Tichopad A, Khan N, Craig IW, D’Souza UM. Genes within the serotonergic system are differentially expressed in human brain. BMC Neurosci.10, 50 (2009).
   PubMedGoogle Scholar
• Kaumann AJ, Levy FO. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol. Ther.111(3), 674–706 (2006).
   PubMed Web of Science ®Google Scholar
• Xu J, Jian B, Chu R, Lu Z et al. Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am. J. Pathol.161(6), 2209–2218 (2002).
   PubMedGoogle Scholar
• Ross EM, Roberts WC. The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am. J. Med.79(3), 339–354 (1985).
   PubMed Web of Science ®Google Scholar
• Moss N, Choi Y, Cogan D et al. A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties. Bioorg. Med. Chem. Lett.19(8), 2206–2210 (2009).
   PubMedGoogle Scholar
• Shyu KG. Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure? Circ. Res.104(1), 1–3 (2009).
   PubMed Web of Science ®Google Scholar
• Xu Y, Jones JE, Kohno D et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron60(4), 582–589 (2008).
   PubMed Web of Science ®Google Scholar
• Lam DD, Przydzial MJ, Ridley SH, Yeo GS, Rochford JJ, O’Rahilly S, Heisler LK. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology149(3), 1323–1328 (2008).
   PubMed Web of Science ®Google Scholar
• Morgan M, Chen W, Anderson C, Prosser W, Donahue D, Shanahan W. Pharmacokinetic properties, metabolism, and tolerability of lorcaserin in health volunteers. Presented at: Annual Meeting of The Obesity Society. Phoenix, AZ, USA, 3–7 October 2008.
   Google Scholar
• Munro JF, Seaton DA, Duncan LJ. Treatment of refractory obesity with fenfluramine. Br. Med. J.2(5514), 624–625 (1966).
   PubMed Web of Science ®Google Scholar
• Stahl KA, Imperiale TF. An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity. Arch. Fam. Med.2(10), 1033–1038 (1993).
   PubMedGoogle Scholar
• Salmela PI, Sotaniemi EA, Viikari J, Solakivi-Jaakkola T, Jarvensivu P. Fenfluramine therapy in non-insulin-dependent diabetic patients: effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism. Diabetes Care4(5), 535–540 (1981).
   PubMedGoogle Scholar
• Hudson KD. The anorectic and hypotensive effect of fenfluramine in obesity. JR. Coll. Gen. Pract.27(181), 497–501 (1977).
   Google Scholar
• O’Connor HT, Richman RM, Steinbeck KS, Caterson ID. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. Int. J. Obes. Relat. Metab. Disord.19(3), 181–189 (1995).
   PubMedGoogle Scholar
• Turner P. Dexfenfluramine. Its place in weight control. Drugs39(Suppl. 3), 53–62 (1990).
   PubMedGoogle Scholar
• Carvajal A, García del Pozo J, Martín de Diego I, Rueda de Castro AM, Velasco A. Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: a meta-analysis. Methods Find. Exp. Clin. Pharmacol.22(5), 285–290 (2000).
   PubMedGoogle Scholar
• Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch. Intern. Med.144(6), 1143–1148 (1984).
   PubMed Web of Science ®Google Scholar
• Weintraub M, Sundaresan PR, Schuster B et al. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin. Pharmacol. Ther.51(5), 595–601 (1992).
   PubMed Web of Science ®Google Scholar
• Weintraub M, Sundaresan PR, Schuster B, Moscucci M, Stein EC. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. Clin. Pharmacol. Ther.51(5), 602–607 (1992).
   PubMed Web of Science ®Google Scholar
• Weintraub M, Sundaresan PR, Schuster B et al. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase. Clin. Pharmacol. Ther.51(5), 608–614 (1992).
   PubMed Web of Science ®Google Scholar
• Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Byrne L. Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication. Clin. Pharmacol. Ther.51(5), 615–618 (1992).
   PubMed Web of Science ®Google Scholar
• Weintraub M, Sundaresan PR, Schuster B. Long-term weight control study. VII (weeks 0 to 210). Serum lipid changes. Clin. Pharmacol. Ther.51(5), 634–641 (1992).
   PubMedGoogle Scholar
• Weintraub M. Long-term weight control study: conclusions. Clin. Pharmacol. Ther.51(5), 642–646 (1992).
   PubMed Web of Science ®Google Scholar
• Smith BM, Smith JM, Tsai JH et al. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J. Med. Chem.51(2), 305–313 (2008).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation112(17), 2735–2752 (2005).
   PubMed Web of Science ®Google Scholar
• Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am. J. Clin. Nutr.56(2), 320–328 (1992).
   PubMed Web of Science ®Google Scholar
• Aubin D, Gagnon A, Grunder L, Dent R, Allen M, Sorisky A. Adipogenic and antiapoptotic protein levels in human adipose stromal cells after weight loss. Obes. Res.12(8), 1231–1234 (2004).
   PubMedGoogle Scholar
• Liese AD, Mayer-Davis EJ, Tyroler HA et al. Development of the multiple metabolic syndrome in the ARIC cohort: joint contribution of insulin, BMI, and WHR. Atherosclerosis risk in communities. Ann. Epidemiol.7(6), 407–416 (1997).
   PubMed Web of Science ®Google Scholar
• Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am. J. Clin. Nutr.79(3), 379–384 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu S, Heshka S, Wang Z, Shen W, Allison DB, Ross R, Heymsfield SB. Combination of BMI and waist circumference for identifying cardiovascular risk factors in whites. Obes. Res.12(4), 633–645 (2004).
   PubMedGoogle Scholar
• Blackburn GL, Waltman BA. Pharmacotherapy to reduce visceral fat. Clin. Cornerstone7(2–3), 52–60 (2005).
   PubMedGoogle Scholar
• Bays H, Dujovne CA. Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr. Atheroscler. Rep.8(2), 144–156 (2006).
   PubMedGoogle Scholar
• Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab.89(6), 2595–2600 (2004).
   PubMed Web of Science ®Google Scholar
• Swinburn BA, Carmichael HE, Wilson MR. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors. Int. J. Obes. Relat. Metab. Disord.20(11), 1033–1040 (1996).
   PubMedGoogle Scholar
• Greco AV, Mingrone G, Capristo E, De, Gaetano A., Ghirlanda G, Castagneto M. Effects of dexfenfluramine on free fatty acid turnover and oxidation in obese patients with Type 2 diabetes mellitus. Metabolism44(2 Suppl. 2), 57–61 (1995).
   PubMedGoogle Scholar
• Ditschuneit HH, Flechtner-Mors M, Dolderer M, Fulda U, Ditschuneit H. Endocrine and metabolic effects of dexfenfluramine in patients with android obesity. Horm. Metab. Res.25(11), 573–578 (1993).
   PubMed Web of Science ®Google Scholar
• Miner JL. The adipocyte as an endocrine cell. J. Anim. Sci.82(3), 935–941 (2004).
   PubMed Web of Science ®Google Scholar
• Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab.89(6), 2548–2556 (2004).
   PubMed Web of Science ®Google Scholar
• Ahima RS. Adipose tissue as an endocrine organ. Obesity.(Silver Spring)14(Suppl. 5) S242–S249 (2006).
   PubMed Web of Science ®Google Scholar
• Caspar-Bauguil S, Cousin B, Galinier A et al. Adipose tissues as an ancestral immune organ: site-specific change in obesity. FEBS Lett.579(17), 3487–3492 (2005).
   PubMed Web of Science ®Google Scholar
• Schaffler A, Muller-Ladner U, Scholmerich J, Buchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocr. Rev.27(5), 449–467 (2006).
   PubMed Web of Science ®Google Scholar
• Connor TJ, Kelly JP. Fenfluramine-induced immunosuppression: an in vivo analysis. Eur. J. Pharmacol.455(2–3), 175–185 (2002).
   PubMedGoogle Scholar
• Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin. Drug Saf.8(3), 317–329 (2009).
   PubMed Web of Science ®Google Scholar
• Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med.337(9), 581–588 (1997).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb. Mortal Wkly Rep.46, 1061–1066 (1997).
   PubMedGoogle Scholar
• Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med.337(24), 1783 (2009).
   Google Scholar
• Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am. Heart J.144(6), 1065–1073 (2002).
   PubMed Web of Science ®Google Scholar
• Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N. Engl. J. Med.339(11), 725–732 (1998).
   PubMed Web of Science ®Google Scholar
• Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation101(17), 2071–2077 (2000).
   PubMed Web of Science ®Google Scholar
• Ryan DH, Bray GA, Helmcke F et al. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes. Res.7(4), 313–322 (1999).
   PubMedGoogle Scholar
• Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA283(13), 1703–1709 (2000).
   PubMed Web of Science ®Google Scholar
• Gardin JM, Constantine G, Davis K, Leung C, Reid CL. Aortic valvular regurgitation: prevalence and clinical characteristics in a predominantly obese adult population not taking anorexigens. Echocardiography23(7), 569–576 (2006).
   PubMedGoogle Scholar
• Smith SA, Waggoner AD, Fuentes LD, vila-Roman VG. Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography. J. Am. Soc. Echocardiogr.22(8), 883–889 (2009).
   PubMed Web of Science ®Google Scholar
• Fitzgerald LW, Burn TC, Brown BS et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol.57(1), 75–81 (2000).
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Savage JE et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation102(23), 2836–2841 (2000).
   PubMed Web of Science ®Google Scholar
• Mekontso-Dessap A, Brouri F et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation113(1), 81–89 (2005).
   PubMedGoogle Scholar
• Roth BL. Drugs and valvular heart disease. N. Engl. J. Med.356(1), 6–9 (2007).
   PubMed Web of Science ®Google Scholar
• Bays H. Adiposopathy–defining, diagnosing, and establishing indications to treat ‘sick fat’: what are the regulatory considerations? US Endocrine Disease2, 12–14 (2006).
   Google Scholar
• Flum DR, Belle SH, King WC et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N. Engl. J. Med.361(5), 445–454 (2009).
   PubMed Web of Science ®Google Scholar
• Krude H, Biebermann H, Schnabel D et al. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4–10. J. Clin. Endocrinol. Metab.88(10), 4633–4640 (2003).
   PubMedGoogle Scholar
• Obregon MJ. Thyroid hormone and adipocyte differentiation. Thyroid18(2), 185–195 (2008).
   PubMed Web of Science ®Google Scholar
• Levacher C, Sztalryd C, Kinebanyan MF, Picon L. Effects of thyroid hormones on adipose tissue development in Sherman and Zucker rats. Am. J. Physiol.246(1 Pt 1), C50–C56 (1984).
   PubMedGoogle Scholar
• Bays H. The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy. Drugs RD7(5), 289–302 (2006).
   PubMedGoogle Scholar
• Nogueiras R, Wiedmer P, Perez-Tilve D et al. The central melanocortin system directly controls peripheral lipid metabolism. J. Clin. Invest.117(11), 3475–3488 (2007).
   PubMed Web of Science ®Google Scholar
• Raposinho PD, White RB, Aubert ML The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes in the male rat. J. Neuroendocrinol.15(2), 173–181 (2003).
   PubMedGoogle Scholar
• Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. EMBO J.19(6), 1290–1300 (2000).
   PubMed Web of Science ®Google Scholar
• Bradley RL, Mansfield JP, Maratos-Flier E, Cheatham B. Melanin-concentrating hormone activates signaling pathways in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab.283(3), E584–E592 (2002).
   PubMed Web of Science ®Google Scholar
• Digby JE, Chen J, Tang JY, Lehnert H, Matthews RN, Randeva HS. Orexin receptor expression in human adipose tissue: effects of orexin-A and orexin-B. J. Endocrinol.191(1), 129–136 (2006).
   PubMed Web of Science ®Google Scholar